4-phenylbutanoyl-L-leucine | 117611-45-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-phenylbutanoyl-L-leucine
• 英文别名: L-Leucine, N-(1-oxo-4-phenylbutyl)-；(2S)-4-methyl-2-(4-phenylbutanoylamino)pentanoic acid
• CAS: 117611-45-7
• 化学式: C₁₆H₂₃NO₃
• 分子量: 277.364
• InChiKey: ZXHZVSUXSLRNAU-AWEZNQCLSA-N

物化性质

• 沸点：
  495.5±38.0 °C(Predicted)
• 密度：
  1.085±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-phenylbutanoyl-L-leucine 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.0h， 生成 (S)-N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-methyl-2-(4-phenylbutanamido)pentanamide hydrochloride
  参考文献：
  名称：

  Development of target protein-selective degradation inducer for protein knockdown

  摘要：

  Our previous technique for inducing selective degradation of target proteins with ester-type SNIPER (Specific and Nongenetic Inhibitor-of-apoptosis-proteins (IAPs)-dependent Protein ERaser) degrades both the target proteins and IAPs. Here, we designed a small-molecular amide-type SNIPER to overcome this issue. As proof of concept, we synthesized and biologically evaluated an amide-type SNIPER which induces selective degradation of cellular retinoic acid binding protein II (CRABP-II), but not IAPs. Such small-molecular, amide-type SNIPERs that induce target protein-selective degradation without affecting IAPs should be effective tools to study the biological roles of target proteins in living cells. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.03.057
• 作为产物：
  描述：

  L-亮氨酸甲酯盐酸盐 在 lithium hydroxide monohydrate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 20.0h， 生成 4-phenylbutanoyl-L-leucine
  参考文献：
  名称：

  Development of target protein-selective degradation inducer for protein knockdown

  摘要：

  Our previous technique for inducing selective degradation of target proteins with ester-type SNIPER (Specific and Nongenetic Inhibitor-of-apoptosis-proteins (IAPs)-dependent Protein ERaser) degrades both the target proteins and IAPs. Here, we designed a small-molecular amide-type SNIPER to overcome this issue. As proof of concept, we synthesized and biologically evaluated an amide-type SNIPER which induces selective degradation of cellular retinoic acid binding protein II (CRABP-II), but not IAPs. Such small-molecular, amide-type SNIPERs that induce target protein-selective degradation without affecting IAPs should be effective tools to study the biological roles of target proteins in living cells. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.03.057

文献信息

• [EN] COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF<br/>[FR] COMPOSÉS POUR LE CIBLAGE DE LA PROTÉINE HUNTINGTINE MUTANTE ET LEURS UTILISATIONS
  申请人：CHDI FOUNDATION INC

  公开号：WO2020176424A1

  公开（公告）日：2020-09-03

  The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.

  本公开涉及一般与同时结合突变的亨廷顿蛋白（mHTT）和一个泛素E3连接酶的化合物以及它们作为治疗剂的用途，例如，在治疗由mHTT聚集引起的疾病，比如神经退行性疾病。
• Discovery of Small Molecules that Induce the Degradation of Huntingtin
  作者：Shusuke Tomoshige、Sayaka Nomura、Kenji Ohgane、Yuichi Hashimoto、Minoru Ishikawa

  DOI：10.1002/anie.201706529

  日期：2017.9.11

  neurodegenerative disorder caused by the aggregation of mutant huntingtin (mHtt), and removal of toxic mHtt is expected to be an effective therapeutic approach. We designed two small hybrid molecules (1 and 2) by linking a ligand for ubiquitin ligase (cellular inhibitor of apoptosis protein 1; cIAP1) with probes for mHtt aggregates, anticipating that these compounds would recruit cIAP1 to mHtt and induce

  亨廷顿舞蹈病（HD）是由突变亨廷顿蛋白（mHtt）聚集引起的常染色体显性遗传性神经退行性疾病，而去除有毒mHtt有望成为一种有效的治疗方法。我们通过将泛素连接酶的配体（凋亡蛋白1的细胞抑制剂； cIAP1）与mHtt聚集体的探针连接，设计了两个小的杂种分子（1和2），预期这些化合物将cIAP1募集到mHtt并通过泛素诱导选择性降解-蛋白酶体系统。合成的化合物降低了HD患者成纤维细胞中的mHtt水平，并且似乎是开发HD治疗的有希望的候选者。
• [EN] CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE DÉGRADATION DE PROTÉINE DE LIAISON À L'ÉLÉMENT DE RÉPONSE D'AMP CYCLIQUE (CBP) ET/OU PROTÉINE DE LIAISON E1A ADÉNOVIRALE DE 300 KDA (P300) ET MÉTHODES D'UTILISATION
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2022042707A1

  公开（公告）日：2022-03-03

  Provided are bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof, and methods for identifying such bivalent compounds.

  提供双价化合物（例如，双官能团小分子化合物），包含一种或多种双价化合物的组合物，以及使用双价化合物治疗需要的患者某些疾病的方法，以及鉴定此类双价化合物的方法。
• Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson’s Disease
  作者：Tommi P. Kilpeläinen、Henri T. Pätsi、Reinis Svarcbahs、Ulrika H. Julku、Tony S. Eteläinen、Hengjing Cui、Samuli Auno、Nina Sipari、Susanna Norrbacka、Teppo O. Leino、Maria Jäntti、Timo T. Myöhänen、Erik A. A. Wallén

  DOI：10.1021/acs.jmedchem.3c00235

  日期：2023.6.8

  reducing α-synuclein (αSyn) dimerization and enhancing protein phosphatase 2A activity in a concentration–response manner, as well as reducing reactive oxygen species production. From the best performing oxazoles, HUP-55 was selected for in vivo studies. Its brain penetration was evaluated, and it was tested in αSyn virus vector-based and αSyn transgenic mouse models of Parkinson’s disease, where it

  脯氨酰寡肽酶（PREP）是人体内广泛分布的丝氨酸蛋白酶，可裂解含脯氨酸的肽；然而，最近的研究表明，它对神经退行性病变致病过程的影响源自直接的蛋白质-蛋白质相互作用（PPI），而不是来自其对某些神经肽水平的调节。我们发现了新型非肽类恶唑类 PREP 抑制剂，它偏离了 PREP 抑制剂已知的构效关系。这些新化合物是 PREP 的 PPI 的有效调节剂，以浓度响应方式减少 α-突触核蛋白 (αSyn) 二聚化并增强蛋白磷酸酶 2A 活性，并减少活性氧的产生。从性能最好的恶唑中，选择HUP-55进行体内研究学习。我们评估了它的大脑渗透性，并在基于 αSyn 病毒载体和帕金森病 αSyn 转基因小鼠模型中进行了测试，它恢复了运动障碍并降低了纹状体和黑质中寡聚 αSyn 的水平。
• Compounds for targeting mutant huntingtin protein and uses thereof
  申请人：CHDI Foundation, Inc.

  公开号：US11389438B2

  公开（公告）日：2022-07-19

  The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.

  本公开总体上涉及同时结合突变亨廷汀蛋白（mHTT）和泛素 E3 连接酶的化合物及其作为治疗剂的用途，例如，用于治疗疾病，如由 mHTT 聚合引起的神经退行性疾病。